Pfizer CentreOne Header Pfizer CentreOne Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Kyorin Pharmaceutical","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Urology","graph2":"Approved"},{"orgOrder":0,"company":"Kyorin Pharmaceutical","sponsor":"Sumitomo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kyorin And Sumitomo Pharma Enter Into License Agreement Of Vibegron In Taiwan And Other Asian Countries","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Urology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Kyorin Pharmaceutical

    Menu

    Kyorin Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Kyorin Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kyorin And Sumitomo Pharma Enter Into License Agreement Of Vibegron In Taiwan And Other Asian Countries

              Details:

              KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the Compound.

              Lead Product(s): Vibegron

              Therapeutic Area: Urology Product Name: Gemtesa

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sumitomo

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kyorin Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron

              Details:

              Based on this agreement, Eisai will acquire exclusive development and marketing rights from Kyorin for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.

              Lead Product(s): Vibegron

              Therapeutic Area: Urology Product Name: Gemtesa

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eisai

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 31, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Evonik
              AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
              Post Enquiry
              POST ENQUIRY